

January 4, 2021



BiomX to Present at Upcoming January Investor Conferences

NESS ZIONA, Israel--(BUSINESS WIRE)-- BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that Jonathan Solomon, Chief Executive Officer, will participate in the following upcoming investor conferences.

Event: H.C. Wainwright BioConnect Conference

Dates: January 11-14, 2021

Time: Playback available 6 a.m. EST January 11

Webcast link: [BiomX - HCW BioConnect Conference Playback](#)

The webcast will also be available in the Events section of the BiomX website at www.biomx.com.

Event: Oppenheimer Virtual Banking Meeting

Dates: January 11-14, 2021

1x1 meetings only

About BiomX

BiomX is a clinical-stage biotechnology company developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as target bacteria in the treatment of chronic diseases, such as inflammatory bowel disease, primary sclerosing cholangitis, cystic fibrosis and colorectal cancer. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.

Additional information is available at www.biomx.com, the content of which does not form a part of this press release.

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20210104005096/en/>

Noel Kurdi, BiomX
VP Investor Relations and Strategy
(646) 241-4400
noelk@biomx.com

Media contact:
Rich Allan, Solebury Trout
(646) 378-2958
rallan@soleburytrout.com

Source: BiomX Inc.

